InVivo Therapeutics Holdings Corporation (NVIVQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
InVivo Therapeutics Holdings Corporation (NVIVQ) trades at $0.37 with AI Score 46/100 (Grade C). InVivo Therapeutics Holdings Corp. Market cap: $1.15M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for NVIVQ: NVIVQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NVIVQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NVIVQ: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
InVivo Therapeutics Holdings Corporation (NVIVQ) Healthcare & Pipeline Overview
InVivo Therapeutics Holdings Corp., a clinical-stage biotechnology company, focuses on developing the Neuro-Spinal Scaffold for spinal cord injury treatment. Utilizing biocompatible polymers, the company aims to provide a structural support for cellular attachment and tissue regeneration. Currently operating with a small team, InVivo navigates the challenges of the biotechnology sector.
What Is the Investment Thesis for NVIVQ?
InVivo Therapeutics Holdings Corp. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing a novel treatment for spinal cord injuries (SCI) with its Neuro-Spinal Scaffold offers significant potential, but also faces considerable challenges. Key value drivers include successful clinical trial outcomes demonstrating the efficacy and safety of the Neuro-Spinal Scaffold, leading to regulatory approval and commercialization. Growth catalysts involve securing strategic partnerships for manufacturing and distribution, as well as expanding the application of the Neuro-Spinal Scaffold to other neurological conditions. However, potential risks include clinical trial failures, regulatory hurdles, and competition from alternative SCI treatments. The company's small size and limited resources also pose challenges to its ability to execute its development and commercialization plans. Investors should carefully consider the inherent uncertainties and potential for significant losses associated with investing in a clinical-stage biotechnology company like InVivo Therapeutics.
Based on FMP financials and quantitative analysis
NVIVQ Key Highlights
InVivo Therapeutics focuses on developing the Neuro-Spinal Scaffold for spinal cord injuries.
- The Neuro-Spinal Scaffold is composed of biocompatible and bioresorbable polymers.
- The company is a clinical-stage biotechnology company, navigating regulatory pathways.
- InVivo Therapeutics operates with a small team of six employees.
- The company's success depends on positive clinical trial outcomes and commercialization of its technology.
Who Are NVIVQ's Competitors?
NVIVQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ELVAY Evolva Holding S.A. | $1.16 | +0.00% | 38 | |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NVIVQ's Key Strengths?
Novel Neuro-Spinal Scaffold technology.
- Focus on unmet medical need in spinal cord injuries.
- Proprietary biopolymer scaffolding platform.
- Potential for significant market opportunity.
What Are NVIVQ's Weaknesses?
Small company with limited resources.
- Clinical-stage with no approved products.
- Dependence on successful clinical trial outcomes.
- High cash burn rate.
What Could Drive NVIVQ Stock Higher?
Clinical trial results for the Neuro-Spinal Scaffold.
- Potential strategic partnerships for manufacturing and distribution.
- Regulatory submissions and approvals.
- Expansion into new therapeutic areas.
- Development of next-generation scaffolds.
What Are the Key Risks for NVIVQ?
Negative return on equity (-60.1%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from alternative SCI treatments.
- Limited funding and potential for dilution.
- Dependence on key personnel.
What Are the Growth Opportunities for NVIVQ?
- Expansion into New Therapeutic Areas: InVivo Therapeutics could explore expanding the application of its biopolymer scaffolding technology to other neurological conditions beyond spinal cord injuries. This could include developing scaffolds for treating traumatic brain injuries, stroke, or neurodegenerative diseases. The market for neurological disorder treatments is substantial, with a global market size estimated at over $100 billion. This expansion would require additional research and development efforts, but it could significantly broaden InVivo's addressable market and revenue potential. Timeline: 3-5 years.
- Strategic Partnerships for Manufacturing and Distribution: InVivo Therapeutics could pursue strategic partnerships with established medical device manufacturers and distributors to scale up production and commercialize its Neuro-Spinal Scaffold. Partnering with companies that have existing infrastructure and expertise in these areas could accelerate the product's market entry and reduce the company's capital expenditures. This would allow InVivo to focus on its core competencies in research and development. Timeline: 1-2 years.
- Geographic Expansion: InVivo Therapeutics could expand its clinical trials and commercialization efforts to international markets, such as Europe and Asia. These markets represent significant growth opportunities due to their large populations and increasing healthcare spending. However, geographic expansion would require navigating different regulatory requirements and cultural nuances. Timeline: 2-4 years.
- Development of Next-Generation Scaffolds: InVivo Therapeutics could invest in research and development to create next-generation scaffolds with enhanced properties, such as improved biocompatibility, biodegradability, or drug delivery capabilities. These advancements could further improve the efficacy and safety of the Neuro-Spinal Scaffold and differentiate it from competing products. Timeline: 3-5 years.
- Personalized Medicine Approach: InVivo Therapeutics could explore a personalized medicine approach by tailoring its Neuro-Spinal Scaffold to individual patient characteristics, such as the severity and location of their spinal cord injury. This could involve using advanced imaging techniques and biomarkers to identify patients who are most likely to benefit from the scaffold. A personalized approach could improve treatment outcomes and increase the adoption of the Neuro-Spinal Scaffold. Timeline: 4-6 years.
What Are NVIVQ's Competitive Advantages?
- Proprietary biopolymer scaffolding technology.
- Patents protecting the Neuro-Spinal Scaffold.
- Clinical trial data demonstrating efficacy.
- First-mover advantage in a niche market.
What Does NVIVQ Do?
InVivo Therapeutics Holdings Corp., founded in 2003 and headquartered in Cambridge, Massachusetts, is a research and clinical-stage biomaterials and biotechnology company dedicated to developing and commercializing innovative biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). The company's primary focus is the Neuro-Spinal Scaffold, an implant designed to promote spinal cord repair by providing a biocompatible and bioresorbable structure. The scaffold is composed of Poly lactic-co-glycolic acid (PLGA), a polymer widely used in resorbable sutures, and Poly-L-Lysine, a positively charged polymer that enhances cellular attachment. InVivo's Neuro-Spinal Scaffold is intended to offer structural support and guidance for nerve regeneration at the injury site. The company's approach involves creating an environment conducive to cellular growth and tissue repair, potentially improving functional outcomes for patients with SCI. As a clinical-stage company, InVivo has been involved in clinical trials to evaluate the safety and efficacy of its Neuro-Spinal Scaffold. The company is navigating the complex regulatory landscape and seeking to demonstrate the clinical benefits of its technology. With a small team of six employees, InVivo faces the challenges of resource constraints and the need for strategic partnerships to advance its research and development efforts. The company's success hinges on the successful completion of clinical trials and the eventual commercialization of its Neuro-Spinal Scaffold.
What Products and Services Does NVIVQ Offer?
- Develop biopolymer scaffolding devices.
- Focus on treatments for spinal cord injuries (SCI).
- Create the Neuro-Spinal Scaffold implant.
- Utilize biocompatible and bioresorbable polymers.
- Promote cellular attachment and tissue regeneration.
- Conduct research and clinical trials.
How Does NVIVQ Make Money?
- Develop and patent biopolymer scaffolding technology.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval for commercialization.
- Potentially partner with manufacturers and distributors.
What Industry Does NVIVQ Operate In?
InVivo Therapeutics operates within the biotechnology industry, which is characterized by high levels of innovation, risk, and regulation. The market for spinal cord injury (SCI) treatments is driven by the unmet medical needs of individuals affected by SCI. The competitive landscape includes companies developing pharmaceutical, surgical, and rehabilitation-based therapies for SCI. InVivo's Neuro-Spinal Scaffold represents a novel approach to SCI treatment, but it faces competition from established and emerging therapies. The biotechnology industry is subject to evolving regulatory standards and reimbursement policies, which can impact the commercial viability of new products. Companies must navigate complex clinical trial requirements and demonstrate the safety and efficacy of their products to gain regulatory approval.
Who Are NVIVQ's Key Customers?
- Hospitals and medical centers.
- Spinal cord injury patients.
- Neurosurgeons and orthopedic surgeons.
- Rehabilitation centers.
Company Profile
InVivo Therapeutics Holdings Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Richard M. Toselli. NVIVQ has traded publicly since 2010.
NVIVQ Valuation & Market Position
With a $1.15M market cap, InVivo Therapeutics Holdings Corporation sits in the micro-cap segment of the market. Relative to its peer group, NVIVQ's quantitative score of 46/100 is below the peer average of 68/100.
Key Financial Metrics
Return on equity for InVivo Therapeutics Holdings Corporation stands at -60.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -54.1%, showing how much profit it generates from its asset base. A current ratio of 7.13 indicates the company holds enough short-term assets to cover its near-term obligations.
NVIVQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its potential.
- Positive community sentiment has emerged around InVivo's innovative approaches to spinal cord injury treatments, attracting attention from biotech enthusiasts.
- Recent developments in clinical trials have shown promising results, bolstering investor optimism about the company's product pipeline.
- Increased media coverage and discussions on social platforms highlight growing interest in the company's mission and technology.
Bear Case
- Concerns about regulatory hurdles remain, as the biotech sector often faces scrutiny that can delay product approvals and market entry.
- Market sentiment is mixed, with some investors expressing skepticism about the scalability of InVivo's technologies in a competitive landscape.
- Recent financial reports have raised questions about cash flow sustainability, leading to concerns about the company's ability to fund ongoing research.
- Community discussions reveal a faction of investors worried about the long timeline for potential commercialization, which could dampen enthusiasm.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NVIVQ Latest News
No recent news available for NVIVQ.
NVIVQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NVIVQ.
Price Targets
Wall Street price target analysis for NVIVQ.
NVIVQ MoonshotScore
What does this score mean?
The MoonshotScore rates NVIVQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Richard M. Toselli
Unknown
Information about Richard M. Toselli's specific background is not available in the provided context. However, typically, a CEO in a biotechnology company has a strong scientific or medical background, combined with business acumen. They often have experience in drug development, clinical trials, and regulatory affairs. A CEO's background often includes advanced degrees in science, medicine, or business administration.
Track Record: Information about Richard M. Toselli's specific track record is not available in the provided context. However, a CEO's track record in a biotechnology company is often evaluated based on their ability to secure funding, advance products through clinical trials, obtain regulatory approvals, and establish strategic partnerships. Their leadership in driving innovation and creating shareholder value is also considered.
NVIVQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that InVivo Therapeutics may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to limited regulatory oversight and may not be required to file regular financial reports with the SEC. This lack of transparency can make it more difficult for investors to assess the company's financial health and prospects compared to companies listed on major exchanges like the NYSE or NASDAQ, which have stricter listing requirements and reporting obligations.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial information, if any.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the potential risks and rewards of investing in the company.
- Consult with a qualified financial advisor.
- Be aware of the potential for significant losses.
- Company has been in operation since 2003.
- Focus on developing treatments for spinal cord injuries.
- Involvement in clinical trials.
- Development of proprietary biopolymer scaffolding technology.
- Headquartered in Cambridge, Massachusetts, a hub for biotechnology companies.
Common Questions About NVIVQ (Healthcare)
What does the AI Score mean for NVIVQ?
NVIVQ holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company focused on developing and commercializing biopolymer scaffolding devices for spinal cord …
What does InVivo Therapeutics Holdings Corporation do?
InVivo Therapeutics Holdings Corp. is a biotechnology company focused on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). Their primary product is the Neuro-Spinal Scaffold, an implant designed to provide structural support and promote nerve regeneration at the injury site.
What do analysts say about NVIVQ stock?
As of March 16, 2026, there is no available analyst coverage or consensus rating for NVIVQ stock. Given the company's OTC listing and limited financial disclosure, it is unlikely that major brokerage firms or research institutions provide in-depth analysis.
What are the main risks for NVIVQ?
The main risks for InVivo Therapeutics include clinical trial failures, regulatory hurdles, and competition from alternative SCI treatments. As a clinical-stage company, InVivo's success depends on the successful completion of clinical trials and the eventual regulatory approval of its Neuro-Spinal Scaffold.
What are the key factors to evaluate for NVIVQ?
InVivo Therapeutics Holdings Corporation (NVIVQ) holds an AI score of 46/100 (low). InVivo Therapeutics Holdings Corp. presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does NVIVQ data refresh on this page?
NVIVQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NVIVQ's recent stock price performance?
InVivo Therapeutics Holdings Corporation (NVIVQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel Neuro-Spinal Scaffold technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NVIVQ overvalued or undervalued right now?
InVivo Therapeutics Holdings Corporation (NVIVQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NVIVQ before investing?
Before investing in InVivo Therapeutics Holdings Corporation (NVIVQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing and disclosure status.
- AI analysis is pending and may provide further insights.